Study of the use of zoledronic acid in pediatric patients with osteogenesis imperfecta at the Fernandes Figueira Institute (IFF/Fiocruz)
DOI:
https://doi.org/10.33448/rsd-v15i1.50474Keywords:
Bisphosphonates, Bones fractures, Osteogenesis imperfecta, Zoledronic acid, Drug therapy.Abstract
Osteogenesis Imperfecta (OI) is a rare genetic disorder characterized by bone fragility and wide clinical variability. This study aimed to evaluate the use of zoledronic acid in pediatric patients with OI treated at the Fernandes Figueira Institute (IFF/Fiocruz), describing the clinical profile, therapeutic response, and safety. This retrospective study was conducted between April 2024 and August 2025 and was based on the medical record review of 40 patients aged 2 to 18 years. An equal distribution between sexes was observed, with higher frequency of OI types I, IV, and III. Intravenous pamidronate was the most frequently used initial bisphosphonate, followed by oral alendronate as a transition strategy, while zoledronic acid was subsequently incorporated into the therapeutic regimen of all patients. Adverse events were more common with pamidronate (32.5%) than with zoledronic acid (17.5%), including fever, bone pain, headache, and gastrointestinal symptoms. Before zoledronic acid use, all patients had a history of fractures; after its introduction, only 12.5% reported new episodes, demonstrating a marked reduction. Subjective perception of clinical improvement was recorded in 7.5% of patients. NTX (n=3) and DEXA (n=2) results were insufficient for conclusions regarding bone remodeling or mineral density. Despite limitations related to the scarcity of complementary exams, the findings suggest clinical benefit of zoledronic acid, reinforcing its potential to reduce fractures and improve OI management in pediatric patients within the Brazilian public health context.
References
Barros, E. R., Saraiva, G. L., de Oliveira, T. P., & Lazaretti-Castro, M. (2012). Safety and efficacy of a 1-year treatment with zoledronic acid compared with pamidronate in children with osteogenesis imperfecta. Journal of Pediatric Endocrinology & Metabolism, 25(5–6), 485–491. https://doi.org/10.1515/jpem-2012-0016
Bishop, N., Arundel, P., Clark, E., Dimitri, P., Farr, J., Jones, G., & Ward, L. M. (2016). Fracture prediction and the definition of osteoporosis in children and adolescents: The ISCD 2013 pediatric official positions. Journal of Clinical Densitometry, 17(2), 275–280. https://doi.org/10.1016/j.jocd.2014.01.004
Cestari, C. G., et al. (2022). Osteogênese imperfeita: Revisão de literatura e relato de casos. Revista Unilago, 2(1).
Forlino, A., & Marini, J. C. (2016). Osteogenesis imperfecta. The Lancet, 387(10028), 1657–1671. https://doi.org/10.1016/S0140-6736(15)00728-X
George, S., et al. (2015). Short-term safety of zoledronic acid in young patients with bone disorders: An extensive institutional experience. The Journal of Clinical Endocrinology & Metabolism, 100(11), 4163–4170. https://doi.org/10.1210/jc.2015-2680
Glorieux, F. H., Bishop, N. J., Plotkin, H., Chabot, G., Lanoue, G., & Travers, R. (1998). Cyclic administration of pamidronate in children with severe osteogenesis imperfecta. The New England Journal of Medicine, 339(14), 947–952. https://doi.org/10.1056/NEJM199810013391402
Kumar, A., Saikia, U. K., Bhuyan, A. K., Baro, A., & Prasad, S. G. (2023). Zoledronic acid treatment in infants and toddlers with osteogenesis imperfecta is safe and effective: A tertiary care centre experience. Indian Journal of Endocrinology and Metabolism, 27(3), 255–259. https://doi.org/10.4103/ijem.ijem_268_22
Land, C., Rauch, F., Montpetit, K., Ruck-Gibis, J., & Glorieux, F. H. (2006). Effect of intravenous pamidronate therapy on functional abilities and level of ambulation in children with osteogenesis imperfecta. The Journal of Pediatrics, 148, 456–460. https://doi.org/10.1016/j.jpeds.2005.10.041
Lima, M. A. F. D., et al. (2014). Contradições das políticas públicas voltadas para doenças raras: O exemplo do programa de tratamento da osteogênese imperfeita no SUS. Ciência & Saúde Coletiva, 19(2), 475–480. https://doi.org/10.1590/1413-81232014192.15582012
Luís, V. L. F. (2013). Osteogenesis imperfecta: Diagnóstico, tratamento e prognóstico (Dissertação de mestrado). Universidade do Porto.
Mahmoud, I., Bouden, S., Sahli, M., Rouached, L., Ben Tekaya, A., Tekaya, R., Saidane, O., & Abdelmoula, L. (2024). Efficacy and safety of intravenous zoledronic acid in the treatment of pediatric osteogenesis imperfecta: A systematic review. Journal of Pediatric Orthopaedics Part B, 33(3), 283–289. https://doi.org/10.1097/BPB.0000000000001104
Melo, P. C. (2015). Osteogênese imperfeita – “Ossos de cristal”: Revisão bibliográfica (Dissertação de mestrado). Universidade da Beira Interior.
Ministério da Saúde. (2022). Protocolo clínico e diretrizes terapêuticas da osteogênese imperfeita (Portaria Conjunta nº 17, de 8 de setembro de 2022).
Montedor, T. S., et al. (2023). Osteogênese imperfeita: Uma revisão literária. Contribuciones a las Ciencias Sociales, 16(9), 18683–18696. https://doi.org/10.55905/revconv.16n.9-288
Otaify, G. A., et al. (2020). Zoledronic acid in children with osteogenesis imperfecta and Bruck syndrome: A 2-year prospective observational study. Osteoporosis International, 27(1), 81–92. https://doi.org/10.1007/s00198-015-3216-9
Paiva, D. F., et al. (2018). Percepções de pessoas com osteogênese imperfeita acerca das intervenções terapêuticas ocupacionais e possibilidades de cuidado. Cadernos Brasileiros de Terapia Ocupacional, 26(2), 399–407. https://doi.org/10.4322/2526-8910.ctoAO1135
Pereira, A. S., et al. (2018). Metodologia da pesquisa científica [e-book]. Editora da UFSM.
Rauch, F., et al. (2006). Pamidronate in children and adolescents with osteogenesis imperfecta: Effect of treatment discontinuation. The Journal of Clinical Endocrinology & Metabolism, 91(4), 1268–1274. https://doi.org/10.1210/jc.2005-2413
Ribeiro, V. C. C. (2021). Osteogênese imperfeita: Novas tecnologias na prevenção de fraturas – Uma revisão sistemática de literatura (Dissertação de mestrado). Universidade Federal da Bahia.
Sánchez-Sánchez, L. M. (2015). Ácido zoledrónico (zolendronato) en niños con osteogénesis imperfecta. Gaceta Médica de México, 152(2), 164–168.
Shitsuka, R., et al. (2014). Matemática fundamental para a tecnologia (2ª ed.). Editora Érica.
Vuorimies, I., et al. (2011). Zoledronic acid treatment in children with osteogenesis imperfecta. Journal of Bone and Mineral Research, 26(9), 2187–2194. https://doi.org/10.1159/000323368
Ward, L., et al. (2016). Bone health and osteoporosis in children and adolescents. Pediatrics, 138(4), e20160296. https://doi.org/10.1542/peds.2016-0296
Downloads
Published
Issue
Section
License
Copyright (c) 2026 Marcele Ribeiro Valente, Lion Schwarzenegger Gabriel Silva Brasileiro, Jéssica de Sá Azevedo, André Rodrigues Pinto, Luciana Moutinho del Estal, Juan Clinton Llerena Junior
This work is licensed under a Creative Commons Attribution 4.0 International License.
Authors who publish with this journal agree to the following terms:
1) Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution License that allows others to share the work with an acknowledgement of the work's authorship and initial publication in this journal.
2) Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgement of its initial publication in this journal.
3) Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) prior to and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work.
